Chronic Lymphocytic Leukemia


American Society of Hematology's 2012 Annual Meeting

The Hope for Personalized Medicine in Myeloma

Dr. Mario Boccadoro shares his perspective on the improving prospects for patients with the disease and comments on efforts to personalize treatment for each patient.

Published:

An Advocate's Perspective on the Latest Developments in Myeloma

Susie Novis, co-founder of the International Myeloma Foundation, joins Andrew at the 2012 ASH meeting to share her perspective on news being presented for patients.

Published:

Myeloma Advocate Perspective: What ASH 2012 News Means for Patients

Patient advocate, Jack Aiello puts significant news for myeloma patients into perspective.

Published:

Effective Therapies for Myeloma Patients After Disease Relapse

Dr. William Bensinger, myeloma expert from the Seattle Cancer Care Alliance, discusses research results that offer hope for patients who experience disease relapse after an allogeneic stem cell transplant.

Published:

Research Efforts Focus on Increasing Treatment Response for Multiple Myeloma Patients

Dr. William Bensinger shares results from a study reported at ASH 2012 using an older drug, amifostine, in a new way; protecting patients from toxicity while patients receive higher and more effective doses of cancer-fighting drugs.

Published:

Promising Early Results From Triple Drug Combination for Myeloma Patients

Dr. William Bensinger details results from a phase l trial reported ASH 2012 testing a new, triple drug combination to help relapsed/refractory multiple myeloma patients.

Published:

ASH President Urges Support For Research Funding

The American Society of Hematology President, Dr. Janis Abkowitz, shares a call to action and urges support for continued research funding.

Published:

A Personal Perspective on CLL and Myelofibrosis Progress

Andrew Schorr shares his optimism while attending the 2012 American Society of Hematology meeting in Atlanta, Georgia.

Published:

Expert Perspective on CLL Treatment and Research Complexities and Obstacles

Dr. Michael Keating shares his perspectives on some complex research surrounding CLL treatment expansion.

Published:

Dr. Michael Keating on Aggressive CLL Subtypes

Dr. Michael Keating talks about different approaches for combating aggressive subtypes of CLL.

Published:

UK Specialist Excited About New, Oral Medicines for CLL

Dr. Claire Dearden, discusses the latest data demonstrating that ibrutinib is highly effective while other oral medications show promise in clinical research.

Published:

An Expert's Perspective: Why New CLL Treatments Supersede FCR

Dr. Jeff Sharman discusses how treatments such as chemotherapy and FCR will be a thing of the past while targeted therapies continue to advance with the hope of a decrease in toxicty with an increase of efficacy.

Published:

The Future of FCR for CLL with Dr. Michael Keating

Dr. Michael Keating provides an update from ASH 2012 on treatment for CLL beyond the FCR regimen.

Published:

New T-Cell "CAR" Research for CLL

Dr. William Wierda discusses updates on Chimeric Antigen Receptor research from ASH 2012.

Published:

Big Changes in CLL Treatment Mean Opportunities for Patients

Dr. John Pagel details important advances that signal a changing treatment landscape in CLL with new options for patients, with updates from ASH 2012

Published:

Results Suggest a Potential Breakthrough in CLL

Drs. John Byrd and Jan Burger share the latest trial data for ibrutinib from ASH 2012

Published:

Ongoing Research Offers Hope for CML Patients

Dr. Jan Cerny explains how this very early animal research is advancing the search for a cure to CML.

Published:

Impact of Cytogenetic and Molecular Response on Long Term Outcomes for CML Patients

Dr. Giuseppe Saglio looks to powerful medicines used in combination to not only knock CML cells down but to knock them out.

Published:

The Latest in CML, A Global Patient-Advocate's Perspective with Jan Geissler

Jan Geissler shares an encouraging report from the 2012 American Society of Hematology annual meeting.

Published:

An Expert’s Perspective on Changing CML Treatment Options

Dr. Moshe Talpaz discusses when the "big guns"of treatment should be used and how there are now treatment options that address certain resistant mutations including the T315I.

Published:

A CML Advocate's Perspective on News from ASH 2012

Executive Director of the National CML Society, Greg Stephens, gives his perspective on news for CML patients from the 2012 ASH Meeting.

Published:

Study Brings Positive Results For the Most Resistant Types of CML

A promising new treatment brings hope for patients with a rare form of leukemia who have run out of treatment options.

Published:

New, Longer Term Research Shows Myelofibrosis Drug to be More Effective, Appears to Extend Survival

New updated research results on Jakafi (ruxolitinib) show positive news to prove to be more effective than hydroxyurea for the treatment of myelofibrosis, according to a new study released at ASH 2012.

Published:

Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations

Dr. Ruben Mesa of the Mayo Clinic, shares his optimism for patients living with myeloproliferative disorders, particularly Myelofibrosis.

Published:

El experto opina: las últimas noticias sobre las Neoplasias Mieloproliferativas (MPN) tras concluir la convención de la Sociedad Americana de Hematología, ASH 2012

El tratamiento de las MPN tiene buenas perspectivas; el Dr. Ruben Mesa nos da su opinión tras asistir a la convención ASH.

Published:

Frontline Therapy in Newly Diagnosed Advanced Hodgkin Lymphoma

Dr. Steven Park updates us on frontline therapy for patients living with Advanced Hodgkin Lymphoma.

Published:

The Importance of Connection: Reaching Out to Myeloma Patients

Internationally recognized myeloma advocate and mentor, Cynthia Chmielewski talks about the importance – and the gift – of reaching out to others with myeloma.

Published:

How Doctors Are Improving Myeloma Outcomes with Personalized Medicine

Personalized medicine is the future of myeloma treatment. Dr. Shaji Kumar discusses how the variety of therapies and better understanding of genetic components are coming together to achieve better outcomes.

Published:

A New Backbone Therapy in the Future for Myeloma Treatment

Research is showing that proteasome inhibitors are incredibly effective at treating many stages of myeloma. Dr. Shaji Kumar talks about how this therapy is becoming a new backbone treatment for myeloma.

Published:

How Doctors Decide Treatments for Newly Diagnosed Myeloma Patients

We're learning a lot about choosing the right treatment plan for each patient. Drs. Shaji Kumar and Noopur Raje talk about what information helps them decide the right plan for each patient.

Published:

Featured Blog
CLL and Lymphoma Drug Approvals: Kudos to the FDA

By Andrew Schorr


Page last updated on March 4, 2014